Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 200.5 JPY 0.92% Market Closed
Market Cap: 289.3B JPY
Have any thoughts about
Sawai Group Holdings Co Ltd?
Write Note

Sawai Group Holdings Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sawai Group Holdings Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Sawai Group Holdings Co Ltd
TSE:4887
Income from Continuing Operations
ÂĄ12.7B
CAGR 3-Years
5%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
ÂĄ290.2B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
ÂĄ250.7B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
ÂĄ155.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
ÂĄ54.7B
CAGR 3-Years
-23%
CAGR 5-Years
-26%
CAGR 10-Years
-7%
No Stocks Found

Sawai Group Holdings Co Ltd
Glance View

Market Cap
272.8B JPY
Industry
Pharmaceuticals

Sawai Group Holdings Co., Ltd. stands as a prominent figure in the pharmaceutical landscape of Japan and beyond, rooted in a steadfast commitment to produce affordable generic medicines. Originating from humble beginnings in 1929, Sawai has evolved into a formidable player in the industry, underpinned by a strategy that blends innovation with an intricate understanding of healthcare needs. Known for its sharp focus on generic pharmaceutical products, the company has carved a niche by prioritizing the development and manufacture of high-quality, cost-efficient medications. This strategic orientation not only aligns with global healthcare trends but also meets the burgeoning demands of an aging population, both domestically and internationally. Central to Sawai's business model is their vertically integrated operation, covering everything from research and development to manufacturing and distribution. This comprehensive approach allows Sawai to maintain strict control over product quality while maximizing operational efficiency. Revenue flows from its diverse product portfolio, which includes a vast array of therapeutic areas such as cardiovascular, digestive, and central nervous system drugs. Moreover, Sawai's expansion into international markets, particularly in the United States through its subsidiary Upsher-Smith Laboratories, broadens its revenue base. By leveraging strategic acquisitions and partnerships, the company continues to fortify its presence on the global stage, all while steadfastly delivering on its promise of making healthcare accessible and affordable.

Intrinsic Value
2 890.58 JPY
Undervaluation 24%
Intrinsic Value
Price

See Also

What is Sawai Group Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
12.7B JPY

Based on the financial report for Mar 31, 2024, Sawai Group Holdings Co Ltd's Income from Continuing Operations amounts to 12.7B JPY.

What is Sawai Group Holdings Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-8%

Over the last year, the Income from Continuing Operations growth was 7%. The average annual Income from Continuing Operations growth rates for Sawai Group Holdings Co Ltd have been 5% over the past three years , -8% over the past five years .

Back to Top